Resources Repository
-
EditorialPublication 2021Scientific and Regulatory Challenges in Designing mHealth Interventions
Scientists looking for innovative ways to deliver health care have long searched for mechanisms that …
Scientists looking for innovative ways to deliver health care have long searched for mechanisms that can enable the right intervention to be delivered at the right time. Traditional delivery mechanisms have been limited both to the availability of a provider (e.g., a physician) and the location of care (e.g., a hospital or outpatient clinic). In recent years, however, numerous technological advancements—including wearable devices, mobile technologies, and the widespread development and use of user-friendly smartphone applications—have…
Health/Medicine | Science/Technology | Technology Assessment | North America -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Health/Medicine | Science/Technology | Preferences/Values | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | North America | Europe -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Health/Medicine | Science/Technology | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
GuidelinesPublication 2011HPV Vaccine Introduction in LMIC's: Guidance on the Use of Cost-Effectiveness Models
This article is a literature review of HPV vaccination models suitable for low-income and middle-income …
This article is a literature review of HPV vaccination models suitable for low-income and middle-income country use to provide information about the feasibility of using such models in a developing country setting. The authors evaluated models in terms of their capacity, requirements, limitations and comparability. Their literature review identified six HPV vaccination models suitable for low-income and middle-income country use and representative of the literature in terms of provenance and model structure. Each model was…
Health/Medicine | Science/Technology | Mathematical Models | Calibration/Validation | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Clinical Care | Global -
EditorialPublication 2019Quality Transparency in Health Care
The immediate promise of using public reporting to increase quality transparency is that it will …
The immediate promise of using public reporting to increase quality transparency is that it will enable consumers to choose the providers best suited to their needs and thereby lead to improved patient outcomes and welfare. Unfortunately, however, early empirical findings failed to detect such anticipated benefits from public reporting. For example, studies have indicated that the launch of the Hospital Compare website and other efforts aimed at increasing quality transparency have not resulted in improved…
Health/Medicine | Policy/Regulation | North America -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Health/Medicine | Probability/Bayes | Test Performance | Technology Assessment | Infectious Diseases | Health Systems | Policy/Regulation | Government/Law | Global | North America -
EditorialPublication 2018Combining A4R and MCDA in Priority Setting for Health
Multiple criteria decision analysis (MCDA) has been proposed as a method for determining the criteria …
Multiple criteria decision analysis (MCDA) has been proposed as a method for determining the criteria to be used in health technology assessment. A standard criticism of MCDA is that it lacks attention to securing legitimacy for its decisions. Accountability for reasonableness (A4R) proposes four conditions (publicity, relevance, revisability and enforcement) that must be met if legitimacy and fairness are to be ascribed to decisions about priority setting.The relevance condition of A4R has been criticized for…
Health/Medicine | Preferences/Values | Priority Setting/Ethics -
GuidelinesPublication 2018Latent TB Infection: Updated & Consolidated Guidelines for Programmatic Management
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation …
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens with no evidence of clinically manifest active TB. Up to one third of the world’s population is estimated to be infected with Mycobacterium tuberculosis, and on average, 5–10% of those who are infected will develop active TB disease over their lifetime. The management of LTBI involves a comprehensive package of interventions: identifying and testing those individuals…
Health/Medicine | Evidence Synthesis | Infectious Diseases | Global -
GuidelinesWeb Portal 2017iDSI Reference Case for Economic Evaluation
This is a reference case which gives 12 principles to guide the planning, conduct and …
This is a reference case which gives 12 principles to guide the planning, conduct and reporting of health economic evaluations in low- and middle-income countries (LMICs). The International Decision Support Group (iDSI) is a network of health, policy and economic experts. It builds on the approaches of the National Institute for Health and Care Excellence (NICE) in the UK, the Health Intervention and Technology Assessment Program (HITAP) in Thailand and the World Health Organization. iDSI…
Health/Medicine | Priority Setting/Ethics | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Global